Samsung Biologics Completes Spin-Off to Strengthen Its Focus as a Pure-Play CDMO

Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO

/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and...

Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary

INCHEON, Korea -- Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after establishment of a new subsidiary company on November 14, 2025. Samsung Bioepis will continue to operate its biosimilar business as a 100% owned s…

Samsung Epis Holdings Launches as Biotech Investment Holding Company

Samsung Epis Holdings President Kim Kyung-ah (Photo courtesy of Samsung Epis Holding) Samsung Epis Holdings officially launched as a biotech investment holding company on Nov. 3, following the completion of a spin-off procedure from Samsung Biologics through a board resolution. Samsung Epis Holdings aims to continue its biosimilar development and commercialization business through its subsidiary Samsung Bioepis, while focusing on research and de…

Samsung Epis Holdings Launches Its New Investment Holding as Samsung Bioepis

Samsung Epis Holdings Co., Ltd. recently announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after the establishment of a new subsidiary company on November 14, 2025. Samsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary o…